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Abstract  
 
Epidemiological research over the past decade suggests that regular cannabis use can adversely 
affect users who initiate use in adolescence and continue to use cannabis more than weekly into 
adulthood. This article summarises the most probable of the adverse health effects of regular 
cannabis use sustained over years as indicated by epidemiological studies that have established 
an association between cannabis use and adverse outcomes, ruled out reverse causation, and 
controlled for plausible alternative explanations. We have also focused on adverse outcomes for 
which there is good evidence of biological plausibility. The focus is on those adverse health 
effects of greatest potential public health significance - those that are the most likely to occur and 
to affect a substantial proportion of regular cannabis users. These most probable adverse effects 
of regular use include: a dependence syndrome, impaired respiratory function, cardiovascular 
disease, adverse effects on adolescent psychosocial development and mental health, and residual 
cognitive impairment.  
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Cannabis has probably been used for medical and quasi-medical reasons by humans for several 
thousand years[1] but societal concerns about the possible adverse health effects of cannabis use 
has been driven by the more recent emergence of recreational cannabis use among young 
people.[2] In developed countries over the past half century, psychoactive preparations of 
cannabis have been increasingly used by adolescents and young adults in social settings to 
enhance sociability and produce euphoria and relaxation. Since cannabis use was first reported 
over 40 years ago by US college students, its use has spread globally, first to other developed 
countries, and more recently, to low and middle income countries.[3, 4] 
 
This paper summarises what is known about the adverse effects of chronic use of cannabis 
beginning in adolescence and continuing into adulthood. We focus on the adverse effects that are 
of greatest potential public health significance, specifically, those health outcomes that are most 
likely to affect a substantial proportion of regular cannabis users. There is good evidence that 
cannabis use increases risks of car crashes in cannabis-impaired drivers and evidence from 
laboratory studies that psychomotor impairment persists for some weeks after cessation in 
regular cannabis users.[5, 6] This topic is not discussed further here because it is dealt with in 
another paper in this special issue. 
 
DEFINING CHRONIC CANNABIS USE 
 
We lack reliable information on the doses of delta-9-tetrahydrocannabinol (THC) and other 
cannabinoids (e.g. cannabidiol) that are commonly used by regular cannabis users.[7] As a 
consequence, epidemiological studies have usually defined “heavy” or “regular” cannabis use as 
daily or near daily use.[2] This pattern of use continued over years most clearly predicts increased 
risks of adverse health effects.[2] 
SEARCH STRATEGY 
 
We searched PubMed and Thompson/Reuters Web of Science citation indexes for articles 
published in the last 10 years on adverse health effects of cannabis to update our earlier review.[8] 
Search terms included “cannabis”, “marijuana abuse”, “marijuana smoking”, “epidemiologic 
studies”, “adverse effects”, “substance related disorders”, “lung diseases”, “respiration 
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disorders”, “cardiovascular diseases”, “coronary disease”, “traffic accidents”, “automobile 
driving”, “mental disorders”, and “adolescent”. Additional papers were identified in references 
cited in these papers, books, edited works and reports. 
 
ASSESSING THE ADVERSE HEALTH EFFECTS OF CANNABIS 
 
As in our earlier paper,[8] we looked for evidence: (1) of an association between cannabis use and 
the outcome in case-control and prospective studies; (2) that reverse causation was an 
implausible explanation of the association (evidence from prospective studies that cannabis use 
preceded the outcome); (3) from prospective studies that controlled for potential confounding 
variables (such as other drug use and characteristics on which cannabis users differed from non-
users); and (4) clinical and experimental evidence that a causal relationship was biologically 
plausible.[2]  
THE HEALTH EFFECTS OF CHRONIC CANNABIS USE 
 
Epidemiological studies have reported associations between chronic cannabis use - defined as 
near daily use over a period of years during adolescence - and various adverse health outcomes 
in young adulthood. These associations are typically quantified as an odds ratio (ratio of the odds 
of the disorder among cannabis users to the odds among nonusers) or a relative risk (the ratio of 
the risks of the disorder among cannabis users and nonusers). 
 
The major challenge in interpreting studies reporting association between regular cannabis use 
and adverse outcomes has been in ruling out alternative explanations of these associations 
because regular cannabis use are more likely to use alcohol, tobacco and other illicit drugs, all of 
which adversely affect health.[2] Regular cannabis users also differ from non-users in ways that 
may affect their risk of behavioural outcomes.[2] Statistical control of confounding has been used 
to assess these relationships but there are epidemiologists who doubt that this strategy can be 
wholly successful.[9] 
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CANNABIS DEPENDENCE  
 
Cannabis dependence is characterised by impaired control over cannabis use and difficulty in 
ceasing use despite harms caused by it. In Australia, Canada and the USA, cannabis dependence 
is the most commonly treated type of drug dependence after alcohol and tobacco,[2] affecting an 
estimated 1%-2% of adults in the past year, and 4%-8% of adults during their lifetime.[2, 10]  
 
The lifetime risk of dependence among all cannabis users has been estimated at about 9%.[10] 
This increases to one in six among users those who initiate in adolescence.[10] The equivalent 
lifetime risks of dependence were 32% for nicotine, 23% for heroin, 17% for cocaine, 15% for 
alcohol and 11% for stimulant users.[11, 12] Those at highest risk of cannabis dependence have a 
history of: poor academic achievement, deviant behaviour in childhood and adolescence, 
rebelliousness, poor parental relationships, and a parental history of drug and alcohol problems.[10] 
 
In laboratory studies, animals and humans develop tolerance to many of the effects of THC.[13] 
Cannabis users who seek help to quit commonly report withdrawal symptoms that include 
anxiety, insomnia, appetite disturbance and depression.[14] 
 
Over the past two decades, increased cannabis use among young adults has been accompanied by 
increasing numbers of persons seeking help in the USA, Europe, and Australia to stop using 
cannabis.[2, 15] Some of this increase may be explained by increased diversion of users into 
treatment by the courts but increases have also occurred in the Netherlands where cannabis use 
has been decriminalised.[16] The adverse health and social consequences of cannabis use reported 
by those who seek treatment for dependence are probably less severe than those reported by 
persons with comparable levels of alcohol or opioid dependence.[2, 17]  
THE RESPIRATORY AND CARDIOVASCULAR RISKS OF CANNABIS SMOKING 
 
Regular cannabis smokers report more symptoms of chronic bronchitis (wheeze, sputum 
production and chronic coughs) than non-smokers (see[18] for a review). The immunological 
competence of the respiratory system in cannabis-only smokers is also impaired, leading to 
increased health service use for respiratory infections.[19] 
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The effects of long term cannabis smoking on respiratory function are less clear.[18] A 
longitudinal study of 1037 New Zealand youths followed until the age of 26[20] found impaired 
respiratory function in dependent cannabis users but this finding was not replicated in a longer 
term follow up of US users.[19] Chronic cannabis smoking has not been found to increase the risk 
of emphysema in 8-20 year follow ups in cannabis smokers in the USA[21, 22] and New 
Zealand.[23] 
Respiratory cancers 
 
Cannabis smoke contains many of the same carcinogens as tobacco smoke, some at higher 
levels[24] and it is mutagenic and carcinogenic in the mouse skin test. In some studies, chronic 
cannabis smokers have shown pathological changes in lung cells that precede the development of 
lung cancer in tobacco smokers,[25] but epidemiological studies have not consistently found 
increased risks of upper respiratory tract cancers in cannabis smokers. Sidney et al.[26] found no 
increased risk of respiratory cancer in an 8·6 year follow up of 64,855 members of the Kaiser 
Permanente Medical Care Program. Zhang et al.[27] reported an increased risk (odds ratio (OR) of 
2) of squamous cell carcinoma of the head and neck among cannabis users in 173 cases and 176 
controls that persisted after adjusting for cigarette smoking, alcohol use, and other risk factors. 
Three other case-control studies of these cancers have failed to find an association with cannabis 
use.[28] 
 
Case-control studies of lung cancer have produced more consistent associations but cannabis 
smoking has often been confounded by cigarette smoking.[29] A Tunisian case-control study of 110 
cases of hospital diagnosed lung cancer and 110 community controls found an association with 
cannabis use (OR= 8·2) that persisted after adjustment for cigarette smoking. A pooled analysis of 
three Moroccan case-control studies also found an elevated risk of lung cancer among cannabis 
smokers but they all also smoked tobacco.[30] A New Zealand case-control study of lung cancer in 
79 adults under the age of 55 years and 324 community controls[31] found a dose-response 
relationship between frequency of cannabis use and lung cancer risk. A US case-control study found 
a simple association between cannabis smoking and head and neck and lung cancers but these 
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associations were no longer significant after controlling for tobacco use.[32] Larger cohort and better 
designed case-control studies are needed to clarify the lung cancer risks from chronic cannabis 
smoking.[28] 
Cardiovascular effects 
 
Cannabis smoking and THC increase heart rate in a dose-related way. Healthy young adults who 
use cannabis daily rapidly develop tolerance[33, 34] to these effects but this may not be true in 
older adults with cardiovascular disease who use less frequently.[33, 34] A case-crossover study by 
Mittleman et al.[35] of 3882 patients who had had a myocardial infarction found that cannabis use 
quadrupled the risk of a myocardial infarction in the hour after use. A prospective study of 1913 
of these adults found a dose-response relationship between cannabis use and mortality over 3·8 
years.[36] These findings are supported by laboratory studies who show that smoking cannabis 
provokes angina in patients with heart disease.[37] A French study found that that 9.5% of 200 
cannabis-related hospitalisations in the Toulouse area between January 2004 and December 2007 
involved cardiovascular disorders, including several myocardial infarctions and a fatal stroke in 
young adults with no other known risk factors for these disorders.[38] 
CHRONIC CANNABIS USE AND BRAIN FUNCTION 
 
Cognitive impairment 
 
It is unclear from cross-sectional studies whether chronic cannabis use impairs cognitive 
performance or whether persons with poorer cognitive functioning are more likely to become 
regular cannabis users.[39] Studies that have matched users and non-users on estimated 
intellectual function before using cannabis,[39] or on cognitive performance assessed before 
cannabis use,[40] have found cognitive impairments in frequent and/or long term cannabis 
users.[40]  
 
Deficits in verbal learning, memory and attention are the most consistently reported in heavy 
cannabis users but these have been variously related to duration of use, frequency of use, and 
cumulative dose of THC.[41, 42] Debate continues about whether these deficits can be attributed to 
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the acute cognitive effects of cannabis, residual effects of chronic use, or the effects of 
cumulative THC exposure on brain functioning.[42] 
 
It is also unclear whether cognitive function completely recovers after cessation of cannabis use. 
Solowij[39, 41] found partial recovery after 2 years abstinence but brain event-related potentials 
still showed a correlation between impaired information processing and years of cannabis use. 
Bolla et al.[43] found persistent dose-related impairment in neurocognitive performance after 28 
days of abstinence in heavy young users (5 years of use) but Pope et al.[44] reported recovery 
after 28 days’ abstinence.  
 
A recent New Zealand longitudinal study assessed changes in IQ between age 13 (before 
cannabis use) and at age 38 in 1,037 New Zealanders born in Dunedin in 1972 or 1973.[45] They 
found that early and persistent cannabis users showed an eight-point decline in IQ compared to 
those who had not used cannabis or not used it in this way. Detailed analyses pointed to 
persistent cannabis use being the most plausible explanation for the decline.  
First, the decline in IQ was largest in those who began using cannabis in adolescence and used 
regularly throughout adulthood. The relationship persisted after statistical adjustment for other 
factors that may affect IQ (such as recent cannabis use, alcohol, tobacco and other drug use, and 
schizophrenia). Second, the same effects were observed in cannabis users who finished high 
school, and the decline persisted after statistically controlling for educational level attained. 
Third, there was some recovery in IQ if users quit, but recovery was limited in participants who 
started smoking cannabis in adolescence and had stopped using for a year or less. There was no 
IQ decline in cannabis users who started in young adulthood and had not used for a year or more 
before follow up. 
Brain structure and function 
 
Regular cannabis use produces a down-regulation of cannabinoid receptors that can be detected 
by positron emission tomography (PET) and persist for up to a month after abstinence has been 
achieved.[46] Functional imaging studies (e.g.[47]) have also shown reduced activity in brain 
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regions involved in memory and attention in chronic cannabis users after 28 days of 
abstinence.[40]  
 
Structural changes have been reported in the hippocampus, prefrontal cortex and cerebellum in 
chronic cannabis users. Yücel et al.[48] reported reduced hippocampal and amygdala volumes in 
15 long term users who had smoked 5 or more joints a day for 10 or more years. These 
reductions increased with the duration of use. Brain imaging studies on larger samples of long-
term cannabis users are needed to see if cognitive impairments in long term users are correlated 
with structural changes in brain areas implicated in memory and emotion.[49] 
 
THE PSYCHOSOCIAL CONSEQUENCES OF ADOLESCENT CANNABIS USE  
 
Educational outcomes 
 
Regular cannabis use and poor educational attainment are associated[50] but it is uncertain 
whether such use: (1) is a contributory cause of poor school performance; (2) is more likely to 
occur in young people with poor educational attainment; or (3) cannabis use and poor 
educational attainment are caused by common factors.[50] Explanations (1) and (2) could both be 
true if poor school performance made regular cannabis use more likely and this in turn further 
impaired school performance. 
 
Longitudinal studies have typically found a relationship between cannabis use before the age of 
15 and early school leaving that has persisted after adjustment for confounders (e.g.[51]). A recent 
meta-analysis of three Australian and New Zealand longitudinal studies[52] confirmed this finding 
by showing that the earlier the age of first cannabis use the lower the chances of completing 
school and post-secondary training. This effect persisted after adjustment for confounders. They 
estimated that early use of cannabis may contribute to as much as 17% of the risk of failing to 
complete high school or post-secondary training. 
It is plausible that impaired educational outcomes are attributable to a combination of: a higher 
pre-existing risk of educational problems in regular cannabis users, the adverse effects of regular 
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cannabis use on learning in school, increased affiliation by regular cannabis users with peers who 
reject school, and a strong desire among younger cannabis users to make an early transition to 
adulthood by leaving school.[50]  
Other illicit drug use 
In the United States, Australia and New Zealand: (1) regular cannabis users are most likely to 
later use heroin and cocaine; and (2) the earlier the age at which a young person first uses cannabis, 
the more likely they are to do so.[53] Three explanations have been offered for these patterns of 
drug use: (1) cannabis users have more opportunities to use other illicit drugs because these are 
supplied by the same black market as cannabis; (2) early cannabis users are more likely to use 
other illicit drugs for reasons that are unrelated to their cannabis use; and (3) the pharmacological 
effects of chronic cannabis increase a young person’s the propensity to use other illicit drugs.[2] 
 
There is support for the first two hypotheses. Young people in the USA who have used cannabis 
report more opportunities to use cocaine at an earlier age.[54] Socially deviant young people (who 
are more likely to use cocaine and heroin) start using cannabis at an earlier age than their peers.[55] 
A simulation study[56] indicates that the second hypothesis may explain the relationships observed 
between cannabis and other illicit drug use.  
 
The second hypothesis has also been tested in longitudinal studies by assessing whether cannabis 
users are more likely to report heroin and cocaine use after statistically controlling for confounders 
(e.g.[57]). Adjustment for confounders (including unmeasured fixed ones using fixed effects 
regression)[58] weakened but did not eliminate the relationship between regular cannabis use and 
the use of other illicit drugs.[59]  
 
Studies of twins discordant for cannabis use have tested the hypothesis that the association is 
explained by a shared genetic vulnerability to use cannabis and other illicit drugs. Lynskey et al.[60] 
found that the twin who had used cannabis was more likely to have used other illicit drugs than the 
co-twin who had not, and the relationship persisted after controlling for non-shared environmental 
factors.  
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CANNABIS USE AND MENTAL HEALTH 
Psychosis and schizophrenia  
Regular cannabis use has associated with psychotic symptoms (disordered thinking, 
hallucinations and delusions) and with psychotic disorders. The latter include schizophrenia 
which is diagnosed in persons who report severe psychotic symptoms over months, and who 
often experience substantial social disability, a loss of motivation, disturbed behaviour and 
cognitive deficits.[61]  
 
A 15 year follow up of 50,465 Swedish male conscripts found that those who had tried cannabis 
by age 18 were 2·4 times more likely to be diagnosed with schizophrenia than those who had 
not.[62] Those who had used cannabis 10 or more times by age 18 were 2·3 times more likely to 
be diagnosed with schizophrenia than those who had not, after statistical adjustment for a limited 
set of confounding variables (a personal history of psychiatric disorder by age 18 and parental 
divorce). 
 
Zammit et al.[63] reported a 27-year follow up of the same cohort that also found a dose-response 
relationship between frequency of cannabis use at age 18 and risk of schizophrenia during the 
follow up. This persisted after statistically controlling for the effects of other confounding 
factors. They estimated that 13% of cases of schizophrenia could be averted if all cannabis use 
were prevented. These results were recently confirmed in a 35 year follow up of the Swedish 
cohort.[64] The Swedish findings have been supported by longitudinal studies in the 
Netherlands,[65] Germany[66] and New Zealand,[67, 68] all of which found that the relationship 
persisted after adjustment for confounders.  
 
A meta-analysis of longitudinal studies reported a pooled odds ratio of 1·4 [95% confidence 
interval (CI): 1·20, 1·65] of psychotic symptoms or psychotic disorder among those who had 
ever used cannabis.[69] The risk of psychotic symptoms or psychotic disorders was higher in 
regular users (odds ratio of 2·09 [95% CI: 1·54, 2·84]). Reverse causation was addressed in most 
of these studies, by excluding cases reporting psychotic symptoms at baseline, or by statistically 
adjusting for pre-existing psychotic symptoms. The common cause hypothesis was harder to 
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exclude because the association between cannabis use and psychosis was attenuated after 
statistical adjustment for potential confounders and no study assessed all confounders.  
 
The evidence is conflicting on whether the incidence of schizophrenia has increased as cannabis 
use has increased among young adults, as would be expected if the relationship were causal. An 
Australian study did not find clear evidence of increased psychosis incidence after steep 
increases in cannabis use during the 1980s and 1990s.[70] One British study[71] suggested that it 
was too early to detect any increased incidence in Britain in the 1990s. A British[72] and a Swiss 
study[73] reported an increased incidence of psychoses in recent birth cohorts but another British 
study failed to do so.[61] It will be difficult to discern whether cannabis use has had any effects on 
incidence because cannabis use produces a modest increase in risk (assuming that the 
relationship is causal) and the interpretation of data on the incidence of psychoses have been 
complicated by changes in diagnosis, the availability of psychiatric services for psychosis, and in 
the quality of data on treated incidence of psychosis. 
 
The risk of developing a psychosis roughly doubles from around 7 in 1000 in nonusers[74] to 14 
in 1000 for regular cannabis users. A doubling of risk is important in persons with an affected 
first degree relative among whom the risk increases from around 10% to 20%.[75] It is 
nonetheless difficult to reduce the population incidence of psychosis by preventing cannabis 
uptake: among men aged 20 to 24, an estimated 5, men would have to be dissuaded from 
smoking cannabis to prevent one case of schizophrenia.[61] 
Cannabis use and affective disorders  
Less consistent, weaker relationships have been found between cannabis use and depression.[76] 
In a follow up of the Swedish cohort, for example, Manrique-Garcia and colleagues found an 
increased risk of depression (1.5 times) in those who reported the heaviest cannabis use at age 
18. The association disappeared after adjustment for confounders.[77] Fergusson and Horwood[78] 
found a dose-response relationship between frequency of cannabis use by age 16 and depressive 
disorder but the relationship was no longer statistically significant after adjusting for 
confounders. A meta-analysis of these studies[69] found a modest association between cannabis 
use and depressive disorders (OR = 1·49 [95% CI: 1·15, 1·94]) but the authors argued that most 
studies had not adequately controlled for confounders, or excluded the possibility that depressed 
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young people are more likely to use cannabis. Similar conclusions were drawn from a combined 
analysis of data from four Australasian birth cohorts.[79]  
 
Bipolar disorders  
Surveys of clinical populations report higher rates of cannabis use disorders among persons 
diagnosed with bipolar disorders (e.g.[80-82]). In a longitudinal study, cannabis use at baseline 
predicted an increased likelihood of manic symptoms in a 3 year follow up of a representative 
sample of young adults.[83] There are also clinical studies suggesting that persons with bipolar 
disorders who continue to use cannabis have more manic episodes and are less satisfied with 
their lives than affected peers who do not use cannabis.[82] These findings suggest that regular 
cannabis use may play a contributory causal role in bipolar disorders but the case is not yet 
compelling because these studies have not adequately controlled for confounding variables or 
ruled out reverse causation.[82] 
Suicide 
Several case-control and cohort studies have found associations between cannabis use and suicide 
in adolescents and young adults but it is unclear whether the relationship is causal. For example, a 
New Zealand case-control study[84] of serious suicide attempts resulting in hospitalisation found 
that 16% of the 302 suicide attempters had a cannabis disorder compared with 2% of the 1028 
community controls. Controlling for social disadvantage, depression and alcohol dependence 
substantially reduced but did not eliminate the association (odds ratio of 2).  
 
The evidence from prospective studies is mixed. Fergusson and Horwood,[78] for example, found a 
dose-response relationship between frequency of cannabis use by age 16 and a self-reported 
suicide attempt but the association did not persist after controlling for confounders. A recent 
analysis of the data from this cohort[85] using sophisticated econometric methods found that more 
than weekly cannabis use increased the likelihood of reporting suicidal ideation in males. Patton et 
al.,[86] by contrast, found that cannabis was only associated with self-harmful behaviour in females, 
a relationship that persisted after controlling for depression and alcohol use. Rasic et al[87] reported 
that heavy cannabis use increased the risk of depression but did not affect suicide risk. A meta-
analysis[69] found that these studies were too heterogeneous to quantify risk, and the authors argued 
that most of these studies had not excluded reverse causation or controlled for confounding.  
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THE HEALTH EFFECTS OF INCREASED THC IN CANNABIS PRODUCTS 
 
The average THC content of cannabis products increased during the late 1990s and early 2000s 
in many developed countries.[88, 89] It is unclear whether increased THC content has been 
accompanied by changes in levels of CBD, a cannabinoid that some argue moderates the adverse 
effects of THC on mental health. Any adverse health effects of increased potency will also 
depend on whether users are able to titrate their dose of THC and on users’ experience with 
cannabis. A higher THC content may increase anxiety, depression and psychotic symptoms in 
naive users, which may deter continued use. At the same time, more potent products may 
increase the risks of developing dependence and psychotic symptoms in regular users if these 
users do not titrate their doses. Adverse effects on the respiratory and cardiovascular systems 
may be reduced if regular users titrate their dose of THC by reducing the amount that they 
smoke. This is a high priority for research. 
 
SUMMARY OF THE ADVERSE HEALTH EFFECTS OF CANNABIS  
 
Chronic cannabis use can produce a dependence syndrome in 1 in 10 users. Regular users have 
higher risks of: chronic bronchitis and possibly impaired respiratory function; and psychotic 
symptoms and disorders, especially if they have a history of psychotic symptoms or a family 
history of these disorders. The most probable adverse psychosocial effect among adolescents 
who become regular users is impaired educational attainment. Regular adolescent cannabis users 
are more likely to use other illicit drugs although the explanation of this relationship remains 
contested.  
 
There is uncertainty about whether a number of other adverse effects associated with regular 
cannabis use are causally related to its use. This is because of the possible confounding effects of 
tobacco smoking in the case of respiratory cancers. In the case of depressive disorders and 
suicide, the direction of the relationship is uncertain. In the case of cognitive performance, the 
size and reversibility of the impairment is unclear. These outcomes, and studies of the typical 
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doses of THC and other cannabinoids in commonly used cannabis preparations, should be 
priorities for research on the health effects of cannabis. 
 
TEXT BOXES 
Box 1: The most probable adverse health effects of chronic cannabis smoking  
 a cannabis dependence syndrome (in around 1 in 10 users);  
 chronic bronchitis and impaired respiratory function in regular smokers; 
 psychotic symptoms and disorders in heavy users, especially those with a 
history of psychotic symptoms or a family history of these disorders; 
 impaired educational attainment among adolescents who use regularly;  
 residual cognitive impairment for up to a month after abstinence;  
 cognitive impairment in those who initiate early and use daily for a decade or 
more. 
 
Box 2: Possible adverse effects of regular cannabis use of which the causal significance remains 
to be assessed  
 respiratory cancers;  
 depressive disorders, mania, and suicide;  
 use of other illicit drugs by adolescents.  
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